MF Rimawi

Treatment of Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer Xenografts With Multiagent HER-Targeted Therapy

Grazia Arpino, Carolina Gutiérrez, Helen A. Weiss et al. · JNCI Journal of the National Cancer Institute · 2007 · 189 citations · Full text

Abstract S3-06: A phase III trial evaluating pCR in patients with HR+, HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/- estrogen deprivation: NRG Oncology/NSABP B-52

MF Rimawi, RS Cecchini, Priya Rastogi et al. · Cancer Research · 2017 · 41 citations

Abstract S3-06, Breast Oncology, Estrogen Receptor +20

PI3 kinase activation and response to trastuzumab or lapatinib in HER-2 overexpressing locally advanced breast cancer (LABC).

Ilenia Migliaccio, M Gutiérrez, Mingxia Wu et al. · Cancer Research · 2009 · 30 citations

Tumor Biology, Trastuzumab Resistance, Breast Oncology +15

Abstract PD1-2: PIK3CA mutations and/or low PTEN predict resistance to combined anti-HER2 therapy with lapatinib and trastuzumab and without chemotherapy in TBCRC006, a neoadjuvant trial of HER2-positive breast cancer patients

Alejandro Contreras, Sabrina Herrera, T Wang et al. · Cancer Research · 2013 · 18 citations

High Pten, Breast Oncology, Pathology +16

Abstract OT3-05-11: Palbociclib after CDK inhibitor and endocrine therapy (PACE): A randomized phase II study of fulvestrant versus palbociclib plus fulvestrant, with and without avelumab, for CDK inhibitor pre-treated HR+/HER2- metastatic breast cancer

EL Mayer, SA Wander, MM Regan et al. · Cancer Research · 2018 · 10 citations

Metastatic Breast Cancer, Oncology, Breast Oncology +15